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Immunosuppressive treatments of systemic lupus (SLE)
remain associated with significant toxicities; hence,
compounds with better toxicity profiles are needed. Di-
hydroorotate dehydrogenase (DHODH) inhibition with
leflunomide has proven to be effective in autoimmune
diseases including SLE, but leflunomide can cause a
variety of side effects. We hypothesized that 4SC-101, a
novel DHODH inhibitor with a more favorable toxicity
profile, would be as effective as high-dose cyclophosph-
amide (CYC) in controlling experimental SLE of female
MRL(Fas)lpr mice. Daily oral gavage of 30, 100, and 300
mg/kg 4SC-101 from 12 to 22 weeks of age was com-
pared with either vehicle or CYC treatment (30 mg/kg/
week, i.p.) in terms of efficacy and toxicity. Three hun-
dred milligrams per kilogram 4SC-101 was as effective
as CYC in depleting spleen autoreactive T cells, B cells,
and plasma cells as well as the respective DNA and RNA
serum autoantibodies. This was associated with a
comparable amelioration of the renal , dermal , and
pulmonary SLE manifestations of MRL(Fas)lpr mice.
However , even the highest dose of 4SC-101 had no
effect on bone marrow neutrophil counts , which
were significantly reduced in CYC-treated mice. To-
gether , the novel DHODH inhibitor 4SC-101 is as
effective as high dose CYC in controlling SLE with-
out causing myelosuppression. Hence, DHODH in-
hibition with 4SC-101 might be suitable to treat
active SLE with fewer side effects thanCYC. (Am J Pathol
2010, 176:2840–2847; DOI: 10.2353/ajpath.2010.091227)
Systemic lupus erythematosus (SLE) is a systemic autoim-
mune disease caused by multiple genetic polymorphisms
and immunostimulatory environmental factors, which com-
monly affects young females.1,2 Mild disease manifesta-
tions such as fatigue, skin rashes, arthralgia, or fever can
usually be controlled by low dose steroids and antimalari-
als.3 In many patients, however, autoimmune inflammation
of solid organs holds the risk of progressive tissue remod-
eling and irreversible organ damage, which requires treat-
ment with potent immunosuppressive drugs.3 For example,
high dose cyclophosphamide (CYC) or mycophenolate
mofetil has proven to be effective to control diffuse prolifer-
ative lupus nephritis in up to 60% to 80% of patients,4–6 and
similar protocols have been applied in SLE patients with
other types of severe immunopathologies.3 However, con-
trolled trials revealed that immunosuppressive treatments
are associated with significant morbidity and mortality in
SLE. For example, in the Aspreva Lupus Management
Study, mycophenolate mofetil caused serious adverse ef-
fects in 27.7% of patients and treatment-related death in
4.9% of patients; CYC caused serious adverse effects in
22.8% of patients and treatment-related death in 2.8% of
patients.6 Most of the adverse effects and deaths were
related to serious infections caused by the immunosuppres-
sive and unspecific antiproliferative effects of CYC and
mycophenolate mofetil, evident by myelosuppression and
leukopenia. Novel drugs that can control autoimmune tissue
inflammation more specifically, ie, without causing myelo-
suppression, may allow to further improve SLE treatment
and to reduce the toxicity of current treatment protocols.3
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The enzyme dihydroorotate dehydrogenase (DHODH)
catalyzes the fourth step in the de novo biosynthesis of
pyrimidine by converting dihydroorotate to orotate.7 This
process is an important step in rapidly proliferating cells,
hence, DHODH activity is necessary for the rapid expan-
sion of autoreactive lymphocytes in autoimmune diseases.8
Because the - and the -barrel domains of DHODH form a
tunnel to the active site of enzymatic activity, compounds
interacting with the - and the -barrel domains can block
DHODH activity. For example, leflunomide, 5-methyl-N-[4-
(trifluoromethyl) phenyl]-isoxazole-4-carboxamide, inhibits
DHODH by binding into this tunnel.9 Consistent with the role
of DHODH in lymphocyte proliferation, leflunomide has
proven effective and was approved for the treatment of
rheumatoid arthritis and psoriasis arthritis.10,11 Leflunomide
was shown to control lupus nephritis in experimental SLE,12
but this study lacked a detailed description of the autoim-
mune phenotype of experimental SLE, a comparison with
CYC treatment efficacy or of toxicity aspects. Side effects of
leflunomide treatment include diarrhea, arterial hyperten-
sion, liver dysfunction, myelosuppression, and interstitial
lung disease.10 It remains unclear whether these effects
relate to DHODH inhibition or to off-target effects of
leflunomide.
4SC-101, 2-(3-Fluoro-3-methoxybiphenyl-4-carbamoyl)-
cyclopent-1-enecarboxylic acid (formerly SC12267), is a
novel small molecule DHODH inhibitor.13 The chemical
structure of 4SC-101 (Figure 1) is considerably different
from the active metabolite of leflunomide. 4SC-101 inhibits
human DHODH with a half maximal inhibitory concentration
(IC50) value of 134 nmol/L, and the proliferation of phytohe-
magglutinin-stimulated lymphocytes with an IC50 value of
about 13 mol/L.13 4SC-101 inhibits phytohemagglutinin-
induced interleukin-17 secretion from human peripheral
blood mononuclear cells (PBMCs) in a dose-related fashion
with an estimated IC50 of 6 mol/L and independently of
lymphocyte proliferation.14 Because 4SC-101 is active in
rodent models of arthritis and intestinal inflammation
(own unpublished data), the compound is currently
under clinical development for rheumatoid arthritis and
inflammatory bowel disease. Can DHODH inhibition
with 4SC-101 also control severe SLE? We hypothe-
sized 4SC-101 to be effective in controlling experimen-
tal SLE, and we compared its effects with CYC in terms
of efficacy and toxicity.
Materials and Methods
Biochemistry and Pharmacological Profile of
4SC-101
In vitro DHODH inhibition assay mixture contained 50
mol/L decycloubiquinone, 100 mol/L dihydroorotate,
and 60 mol/L 2,6-dichloroindophenol. The amount of
enzyme was adjusted such that an average slope of
approximately 0.2 AU/min will be achieved in the assay
for the positive control (eg, without inhibitor). Measure-
ments were conducted in 50 mmol/L TrisHCl, 150 mmol/L
KCl, 0.1% Triton X-100, and pH 8.0 at 30°C in a final
volume of 1 ml. The components were mixed, and the
reaction was started by adding dihydroorotate. The re-
action was followed spectrophotometrically by measur-
ing the decrease in absorption at 600 nm for 2 minutes.
The assay was linear in time and enzyme concentration.
Inhibitory studies were conducted in a standard assay
with additional variable amounts of inhibitor. For the de-
termination of the IC50 values (concentration of inhibitor
required for 50% inhibition), eight different inhibitor con-
centrations were applied. Each data point was recorded
in triplicates on a single measurement day.
Human PBMCs from healthy human donors were puri-
fied by centrifugation over Ficoll-Hypaque (Sigma-Al-
drich, Taufkirchen, Germany). Purified PBMCs were then
washed twice with phosphate-buffered saline and resus-
pended in RPMI1640 culture medium supplemented with
10% heat inactivated fetal calf serum, 1.5 mmol/L L-glut-
amine, 100 U penicillin/ml, and 100 mg streptomycin/ml.
For stimulation studies, PBMCs were seeded at 1  105
cells/well, stimulated with 2 g/ml phytohemagglutinin,
and treated with compounds at the indicated concentra-
tions for 48 hours. The vehicle for 4SC-101 (4SC AG,
Planegg-Martinsried, Germany) was dimethyl sulfoxide
(Acros Organics, Fischer Scientific GmbH, Niederrau,
Germany). After incubation, proliferation was assessed by
using the cell proliferation colorimetric BrdU-enzyme-linked
immunosorbent assay kit from Roche (Mannheim, Ger-
many) according to the manufacturer’s instructions.
Animals and Experimental Protocol
Eight-week-old female MRLlpr/lpr mice were obtained from
Harlan Winkelmann (Borchen, Germany) and kept under
normal housing conditions in a 12-hour light and dark
cycle. Water and standard chow (Ssniff, Soest, Germany)
were available ad libitum. At the age of 12 weeks, groups
of 11 mice each started to receive either 30, 100, or 300
mg/kg/day 4SC-101 in 100 l of suspension or placebo
suspension only by daily oral gavage. Another group of
MRLlpr/lpr mice received 30 mg/kg CYC once a week by
intraperitoneal injection because this dose potently sup-
presses the autoimmune syndrome in MRLlpr/lpr mice.15
Twelve-week-old mice were selected because in our
hands the presence of serum autoantibodies and albu-
minuria indicate significant systemic autoimmunity and
early lupus nephritis at this age.16 4SC-101 plasma levels
were determined at various time intervals after the first
Figure 1. Structure and biochemistry of 4SC-101. 4SC-101, 2-(3-fluoro-3-me-
thoxybiphenyl-4-carbamoyl)-cyclopent-1-enecarboxylic acid, is a novel inhibitor
of human DHODH discovered by molecular design based on the X-ray structure
of human DHODH. Different from leflunomide, this compound has virtually no
effect on kinases and has therefore a much cleaner pharmacological profile.
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dose. All experiments were performed according to Ger-
man animal protection laws and had been approved by
the local government authorities.
Evaluation of Systemic Lupus
Urinary albumin/creatinine concentration ratios and se-
rum immunoglobulin concentrations were determined by
enzyme-linked immunosorbent assay as previously de-
scribed.17 Two-micrometer paraffin sections for hematoxy-
lin and eosin and periodic acid-Schiff stains were prepared
from skin, lung, and kidney tissues samples following rou-
tine protocols.18 Skin lesions were scored semiquantita-
tively as described.19 In brief, hematoxylin and eosin skin
sections were analyzed for the degree of acanthosis, mildly
(1) to very markedly thickened epidermis (3); hyperkerato-
sis, mildly (1) or markedly increased thickness of the cor-
neal layer (2); interface liquefaction, focal (1) or extensive
damage to the basal cell layer (2); inflammation, sparse (1)
or intense dermal lymphocytic cell infiltrates (2); fibrosis or
mucin deposits, increased dermal cellularity with slight (1)
or markedly thickened extracellular matrix or mucin depos-
its (2); vessels, focal (1) or diffuse (2) distribution of hemor-
rhagic vasodilation; and loss of epidermis, absence (0) or
presence (1) of ulcer or erosion. The severity of the renal
lesions was graded by using the indices for activity and
chronicity as described for human lupus nephritis.20 The
severity of the peribronchial inflammation was graded semi-
quantitatively from 0 to 3. Immunostaining was performed
as previously described.21 The following primary antibodies
were used: rat anti-mouse Mac2 (macrophages, Ceder-
lane, ON, Canada, 1:50); anti-mouse CD3 (1:100, clone
500A2, BD Pharmingen, Heidelberg, Germany); and anti-
mouse IgG1 (1:100, M32015, Caltag Laboratories, Burlin-
game, CA). Glomerular Ig deposits were scored from 0 to 3
on 15 glomerular sections where 0  no glomerular IgG
deposits, 1  trace IgG deposits, 2  moderate IgG de-
posits, and 3 severe IgG deposits. Glomerular cells were
counted in 15 cortical glomeruli per section. Interstitial cells
were counted in 15 high power fields per section. All quan-
titative and semiquantitative analyses were performed by
three blinded observers (Claudia Kanter, Miklos Sardy,
Hans-J. Anders).
Glomerular Filtration Rate
Glomerular filtration rate (GFR) was determined by clear-
ance kinetics of plasma fluorescein isothiocyanate
(FITC)-inulin (Sigma-Aldrich) 5, 10, 15, 20, 35, 60, and 90
minutes after a single intravenous bolus injection.22 Flu-
orescence was determined with 485 nm excitation and
read at 535 nm emission. GFR was calculated based on
a two-compartment model of nonlinear regression by using
a curve-fitting software (GraphPad Prism, GraphPad Soft-
ware, Inc., San Diego, CA).
Flow Cytometry
Flow cytometry was performed by using a FACScalibur
machine using the following primary antibodies: anti-mouse
CD4-APC, CD8-PerCp, CD3-FITC, CD25-PerCp, CD45R-
APC, CD21-FITC, CD23-PE, IgD-PE, IgM-FITC,  light
chain-PE, CD138-APC, 7/4-PE, Ly6G-FITC, CD11c-PE, and
CD40-FITC were procured from BD Pharmingen. Analysis
of bone marrow cells was performed as described.23
Statistical Analysis
Data were expressed as mean  SEM. Comparisons
among groups were performed by using univariate analysis
of variance. Posthoc Bonferroni’s correction was used for
multiple comparisons. A value of P  0.05 indicated statis-
tical significance. Due to the serial sacrifice design (each
blood sample from an individual animal), no statistical eval-
uation of the pharmacokinetic data was performed.
Results
Pharmacodynamics of 4SC-101
DHODH inhibition was confirmed in an in vitro enzyme as-
say, which allows one to monitor the catalytic activity of the
enzyme by indirect measurement of the reduced co-sub-
strate ubiquinone. 4SC-101 caused a concentration-depen-
dent inhibition of DHODH. The inhibition data for 4SC-101 in
different DHODH species are given in Table 1. Human
peripheral blood mononuclear cells isolated from healthy
donors were stimulated with 2 g/ml phytohemagglutinin.
4SC-101 caused a concentration dependent inhibition of
phytohemagglutinin-stimulated PBMC proliferation. The
IC50 values were determined by nonlinear regression of
the inhibition curves by using a Hill equation curve fitting.
The resulting data are given in Table 1. The inhibition of
PBMC proliferation by 4SC-101 could be abrogated by
addition of 50 to 500 mol/L of uridine to the assay
mixture, supporting the inhibition of pyrimidine de novo
synthesis as the mode of action (data not shown).







30 28.4 1.0 229.0 2.3
100 46.0 1.5 499.7 2.3
300 52.1 1.5 583.3 3.0
Cmax, maximal concentration after single injection; tmax, time point of
maximal concentration after single injection; AUC, area under the
curve; t1/2, maximal concentration half time.
Table 1. Pharmacodynamics of 4SC-101
Inhibition of 4SC-101 (IC50)
Human DHODH 0.048  0.006 g/ml (0.134  0.016 mol/L)
Rat DHODH 0.46  0.17 g/ml (1.29  0.47 mol/L)
Mouse DHODH 3.8  0.3 g/ml (10.6  0.7 mol/L)
Human PBMC
proliferation
4.6  2.1 g/ml (12.9  5.9 mol/L)
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Pharmacokinetics of Single Dose 4SC-101 in
MRLlpr/lpr Mice
Pharmacokinetic studies were performed in 12-week-old
female MRLlpr/lpr mice (n  3 for each dose and time
point). Pharmacokinetic parameters were calculated from
geometric mean plasma levels per time point. Area under
the curve was calculated by using the trapezoidal rule
and extrapolated to infinity by adding Cz/z. Key phar-
macokinetic parameters are listed in Table 2. Plasma
concentrations increased with increasing doses of 4SC-
101, though, less than dose-proportionally (Figure 2).
Maximum plasma levels were reached after 60 to 90
minutes, and the terminal half-life was 2.3 to 3 hours. Due
to the lack of data points in the terminal phase, the values
calculated for t1/2 were probably underestimated.
Long-term 4SC-101 Treatment and B and
T Cell Immunity in MRLlpr/lpr Mice
Next we assessed the effects of a long-term exposure
with 4SC-101 on SLE in female MRLlpr/lpr mice. Mice were
treated from 12 to 22 weeks of age with either 30, 100, or
300 mg/kg/day 4SC-101 by daily oral gavage. Additional
groups of mice were treated either with placebo daily oral
gavage or with CYC (30 mg/kg per week, i.p.) to serve as
negative and positive controls, respectively. CYC and
300 mg/kg 4SC-101 were equipotent in reducing the
weight of mesenterical lymph nodes at 22 weeks of age
(Figure 3A). 4SC-101 at a dose of 100 mg/kg was less
effective, and lymph node weight in the 30 mg/kg dose
group was not significantly different from vehicle-treated
MRLlpr/lpr mice (Figure 3A). Flow cytometry of spleen
lymphocyte subsets revealed that 300 mg/kg 4SC-101
and CYC both significantly reduced the numbers of
spleen CD3 lymphocytes, mainly by reducing of CD4
T helper cells and CD4/CD8 double negative “autoreac-
tive” T cells (Figure 3B). By contrast, 300 mg/kg 4SC-101
did not significantly alter the CD8 “cytotoxic” and CD4/
CD25 “regulatory” T cell populations (Figure 3B). The
lower doses of 4SC-101 had no significant effect on T cell
populations in spleens of 22-week-old female MRLlpr/lpr
mice. However, 100 and 300 mg/kg 4SC-101 both signif-
icantly reduced the B220IgMIgD “mature” B cells,
the B220CD21highCD23low “marginal zone” B cells, the
B220CD21lowCD23high “follicular” B cells, and the cyto-
plasmic CD138 plasma cells (Figure 3C). Interest-
ingly, CYC did not significantly affect these B cell popu-
lations in MRLlpr/lpr mice, indicating that 4SC-101 has a
60000
























0 60 120 180 240 300 360 420
0
450 900 1350 1800
Time After dosing (min)
P
Figure 2. Pharmacokinetics of 4SC-101 in mice. Twelve-week-old female
MRLlpr/lpr mice received a single dose of either 30, 100, or 300 mg/kg 4SC-101
by oral gavage, and plasma samples were obtained at different intervals as
indicated. The graph illustrates plasma 4SC-101 levels over time as geometric
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Figure 3. 4SC-101 reduces systemic autoimmunity in MRLlpr/lpr mice. A: Mesenteric lymph node weight was determined at 22 weeks after ten weeks of vehicle,
4SC-101, or CYC treatment. Data are means  SEM. *P  0.05; ***P  0.001 versus vehicle group. B and C: Spleen cell suspensions were prepared for flow cytometry
by using specific antibodies that identify T cell (B) and B cell (C) subsets. Data are expressed as mean percentages of all splenocytes SEM. *P 0.05; **P 0.01 versus
vehicle group. D and E: Serum samples were obtained at 22 weeks of age from mice of all groups, and total serum IgG and IgG isotype levels (D) and anti dsDNA IgG
levels (E) were determined by enzyme-linked immunosorbent assay. Data are means  SEM. *P  0.05; **P  0.01; ***P  0.001 versus vehicle group.
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predominant effect on B cells, which is different to the
immunosuppressive effects of CYC. In addition, 300
mg/kg 4SC-101 and CYC significantly reduced serum
total IgG and IgG isotype levels in 22-week-old female
MRLlpr/lpr mice (Figure 3D). This effect did also apply to
the production of lupus autoantibodies because anti-
dsDNA IgG serum levels were only significantly reduced
in the 300 mg/kg 4SC-101 and CYC groups (Figure 3E).
Thus, reducing T cells is more important than reducing B
cells to suppress hypergammaglobulinemia and autoan-
tibody production in female MRLlpr/lpr mice, which was
achieved by 300 mg/kg 4SC-101 and CYC.
4SC-101 Improves Lupus Nephritis in MRLlpr/lpr
Mice
Female MRLlpr/lpr mice develop and subsequently die
from proliferative immune complex glomerulonephritis
with large similarities to diffuse proliferative lupus nephri-
tis in humans.24 We treated female MRLlpr/lpr mice with
4SC-101, CYC, or vehicle from 12 to 22 weeks of age
because at 12 weeks of age MRLlpr/lpr mice show first
signs of proliferative immune complex glomerulonephritis
and proteinuria.16 After 10 weeks of treatment, vehicle-
treated MRLlpr/lpr mice showed diffuse proliferative immune
complex glomerulonephritis characterized by glomerular
IgG deposits, mesangioproliferative glomerulonephritis,
considerable tubular atrophy, and interstitial fibrosis (Figure
4A). 4SC-101 reduced the glomerular IgG deposits and
improved the lupus-like immune complex glomerulonephri-
tis in female MRLlpr/lpr mice in a dose dependent manner
(Figure 4A) as evidenced by semiquantitative morpho-
metrical evaluation, eg, by assessing the activity and
chronicity scores of lupus nephritis (Figure 4B). The activity
score, a composite score of mostly glomerular abnormali-
ties, and glomerular IgG deposits were significantly re-
duced by 100 as well as by 300 mg/kg 4SC-101 (Figure
4B). The chronicity score, a composite score of glomerular
and interstitial scarring, was significant for the 300 mg/kg
4SC-101 group only. CYC was potent in reducing both
parameters but not significantly different from 300 mg/kg
4SC-101. In 22-week-old vehicle-treated MRLlpr/lpr mice, lu-
pus nephritis was associated with glomerular macrophage
infiltration and a mixed periglomerular and interstitial inflam-
matory cell infiltrate consisting of glomerular and interstitial
Mac2-positive macrophages and interstitial CD3-positive T
cells (Figure 4A). CYC and 100 and 300 mg/kg 4SC-101
reduced renal macrophage and T cell infiltrates (Figure 4C).
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Figure 4. 4SC-101 improves renal histopathology in MRLlpr/lpr mice. A: Renal sections of 22-week-old MRLlpr/lpr mice were stained with periodic acid Schiff and
antibodies for IgG and CD3 (T cells) as indicated. Images are representative for seven to 12 mice in each group (original magnification, 100 [PAS], 400 [IgG],
100 [CD3]). B: Morphometry was performed on IgG and PAS stained sections to quantify glomerular IgG deposits (score ranging from 0 to 3), the lupus nephritis
disease activity index (score ranging from 0 to 24), and the lupus nephritis chronicity index (score ranging from 0 to 12). C: CD3 T cells and Mac2 interstitial
cells were counted in 15 high power fields from renal sections of MRLlpr/lpr mice from all groups. Mac2 cells were also counted in 15 glomeruli from mice of
all groups of MRLlpr/lpr mice from all groups. Data represent means  SEM. *P  0.05; **P  0.01; ***P  0.001 versus vehicle control group; ND, not detected.
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Next we determined the GFR as a functional marker of renal
excretory function and urinary albumin/creatinine ratio as a
marker of proteinuria, ie, glomerular filtration barrier dys-
function. 4SC-101 treatment was associated with an in-
crease of GFR and a decrease of albuminuria in a dose-
dependent manner (Figure 5, A and B). Doses of 100 or 300
mg/kg 4SC-101 were both as effective as CYC in improving
both of these renal function parameters. We conclude that
the dose-dependent impact of 4SC-101 on systemic auto-
immunity translates into anti-inflammatory effects on lupus
nephritis and improvement of renal dysfunction in MRLlpr/lpr
mice.
4SC-101 Reduces Cutaneous and Pulmonary
SLE Manifestations of MRLlpr/lpr Mice
Skin and lungs are also commonly affected by autoimmune
tissue injury in MRLlpr/lpr mice. In vehicle-treated mice, 6 of
11 mice suffered either from facial rash and/or discoid
lesions in the neck area, few of them with neck ulcers.
Histopathological evaluation of neck skin revealed various
degrees of acanthosis, hyperkeratosis, widening of the in-
terface, T cell infiltrates, dermal mucin and collagen depos-
its, and vasodilation (Figure 6A). The quantitative assess-
ment of a composite score of all of these abnormalities
revealed a dose-dependent improvement of skin disease in
4SC-101-treated female MRLlpr/lpr mice (Figure 6B). All of
the aforementioned parameters were significantly improved
by 300 mg/kg 4SC-101 except for dermal fibrosis (Figure
6C). None of the CYC-treated mice revealed any signs of
skin disease. Autoimmune lung disease in MRLlpr/lpr mice
was characterized by moderate to severe peribronchiolar
and perivascular inflammatory cell infiltrates (Figure 7A). All
dose regimens of 4SC-101 were effective in reducing lung
pathology as evidenced by a semiquantitative lung injury
score (Figure 7B). Obviously, higher doses of 4SC-101 are
as potent as CYC to control kidney, skin, and lung pathol-
ogy in autoimmune MRLlpr/lpr mice.
4SC-101 and Bone Marrow Cells in MRLlpr/lpr
Mice
The therapeutic use of CYC is generally limited by myelo-
suppression, potentially causing fatal infectious complica-
tions, a side effect resulting from the unspecific antiprolif-
erative mode of CYC action. We therefore performed flow
cytometry on bonemarrow cell suspensions to compare the
effects of 4SC-101 and CYC on myelosuppression. CYC
treatment significantly reduced the number of neutrophils in
bone marrows to less than 30% and the mixed leukocyte
population (monocytes, T cells and B cells) by 50% com-
pared with vehicle-treated MRLlpr/lpr mice (Figure 8). By
contrast, none of the 4SC-101 dose groups showed re-
duced bone marrow neutrophils (or macrophages) counts.
We therefore conclude that a broad dose range of 4SC-101
does not cause myelosuppression in MRLlpr/lpr mice, which
is one of the major risk factors for infectious complications



































Figure 5. 4SC-101 improves GFR and proteinuria in MRLlpr/lpr mice. At 22
weeks of age, GFR (A) and urinary albumin/creatinine ratios (B) were
determined in MRLlpr/lpr mice from all groups as described in Materials and
Methods. Note the dose-dependent increase in GFR and decline in albumin-
uria in 4SC-101-treated MRLlpr/lpr mice. Data represent means  SEM. *P 
0.05 versus vehicle control group.
Figure 6. 4SC-101 and cutaneous lupus in MRLlpr/lpr mice. MRLlpr/lpr mice of
all groups were regularly checked for skin manifestations, which typically
occur in the facial or neck area. A: Representative images of hematoxylin and
eosin stained skin biopsies from selected groups are shown as indicated
(original magnification,100). A semiquantitative assessment of skin pathol-
ogy allowed to calculate a composite skin injury score (B), which was
derived from adding the scores of seven different criteria (C) as indicated.
CYC-treated mice had no signs of skin disease. Data represent means SEM.
*P  0.05 versus vehicle control group, **P  0.01 versus placebo control.
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Discussion
Immunosuppressants like CYC remain first-line treatment
for severe SLE.3 However, many patients suffer from se-
vere side effects like myelosuppression making patients
susceptible to life threatening infections.2–4 Our data
show that 4SC-101 is as effective as CYC in controlling
SLE in MRLlpr/lpr mice but avoid these side effects.
The novel DHODH inhibitor 4SC-101 acts as a highly
selective inhibitor of the de novo biosynthesis of pyrimi-
dines, which inhibits the expansion of rapidly proliferating
cells. DHODH inhibition was thought to be appropriate in
SLE because the expansion of autoreactive lymphocytes
demands large quantities of pyrimidine to support DNA
synthesis, which renders autoreactive lymphocytes espe-
cially sensitive to the blockade of pyrimidine de novo
synthesis.7 We found that 300 mg/kg of 4SC-101 can
significantly reduce the numbers of CD4/CD8 double
negative “autoreactive” T cells and plasma cells in spleen
without affecting CD4/CD25 “regulatory” T cells. This
suppressive effect was sufficient to significantly reduce
hypergammaglobulinemia and dsDNA autoantibodies as
major hallmarks of polyclonal autoimmunity in SLE. Con-
sistent with the concept of systemic autoimmunity driving
tissue pathology,1,25 the reduction of autoreactive T and
B cells was associated with almost complete prevention
of cutaneous lupus lesions in all layers of the skin, im-
proved renal pathology and function, and significant im-
provement of lung pathology. In terms of toxicity, CYC
treatment caused significant myelosuppression as in our
previous studies.15 Bone marrow 7/4 monocytes and
neutrophils were reduced by CYC treatment but not by
4SC-101, a finding not revealed by a study describing
DHODH inhibition with leflunomide in murine SLE, basi-
cally because bone marrow was not analyzed.12
What is the clinical perspective of DHODH inhibition in
human SLE? A double-blind, randomized, placebo-con-
trolled study proved leflunomide to be effective in control-
ling diverse SLE manifestations in a small number of pa-
tients and during short-term follow-up.26 One patient
withdrew from the study due to liver toxicity, and two pa-
tients discontinued treatment because of hypertension;
both known side effects of leflunomide.7 The same group
determined safety and efficacy of leflunomide in 17 patients
with lupus nephritis with previous treatment-related toxici-
ties, CYC contraindications or lack of response to CYC,
azathioprine, or cyclosporin for at least 6 months.27 Lefluno-
mide induced a partial remission in 13 of 17 patients and a
complete remission in 5 of 17 patients, which serves as
another proof-of-concept that DHODH inhibition can control
severe SLE. However, leflunomide treatment was associ-
ated with hypertension in 6 of 17 patients and infections in
4 of 17 patients.27 Another trial compared efficacy and
safety of leflunomide and CYC in 110 patients with biopsy-
proven diffuse-proliferative lupus nephritis.28 Leflunomide
was found to be equally effective as compared with CYC
but caused the well known side effects.28 It is unknown
whether these side effects are leflunomide-specific or a
result of DHODH inhibition. The observation that lefluno-
mide can induce cutaneous lupus may argue for drug-
specific side effects rather than for DHODH inhibi-
tion.29–31 4SC-101 has been clinically tested in over 140
patients and healthy volunteers so far. In a randomized,
double-blind, placebo-controlled sequential dose esca-
lating phase I study, the safety, tolerability, and pharma-
cokinetics of ascending single oral doses of 4SC-101
(study number SC12267-1-2003) were evaluated in 42
healthy volunteers. In a corresponding phase I trial test-
ing ascending multiple oral doses of 4SC-101 (study
number SC12267-2-2004), additional 24 healthy volun-
teers have been treated with 4SC-101. In a randomized,
double-blind, placebo-controlled phase IIa proof of con-
cept study in rheumatoid arthritis (study number SC12267-
Figure 7. 4SC-101 improves autoimmune lung disease in MRLlpr/lpr mice. A:
Lung sections of 22-week-old MRLlpr/lpr mice were stained with periodic acid
Schiff. Images are representative for 7 to 12 mice in each group (original
magnification, 100). B: Morphometry was used to quantify the peribron-
chiolar and perivascular inflammation by using a score ranging from 0 to 3.
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Figure 8. 4SC-101 and bone marrow cells in MRLlpr/lpr mice. Flow cytometry
was used to quantify neutrophils and monocytes in bone marrows of 22-
week-old female MRLlpr/lpr mice from all treatment groups. Monocytes were
identified as 7/4bri Ly6G. Neutrophils were identified as 7/4Ly6G. Data
are shown as mean percentages  SEM from at least five to six mice in each
group. **P  0.01, ***P  0.001 versus vehicle control group.
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3-2005), a total of 121 patients were randomized to three
treatment groups (about 40 patients per group) to receive
20 mg tablets of 4SC-101, 35 mg tablets of 4SC-101, or
matching placebo tablets once daily for a period of 12
weeks. In all completed trials, no liver toxicity, diarrhea, or
arterial hypertension have been observed as treatment-
related adverse events. 4SC-101 is currently being
tested in two further ongoing phase II clinical trials: the
“ENTRANCE” trial evaluating 4SC-101 in patients with
inflammatory bowel diseases (http://www.clinicaltrials.gov,
identifier: NCT00820365) and the “COMPONENT” trial as-
sessing the efficacy of 4SC-101 in rheumatoid arthritis
patients in combination with methotrexate (http://www.
clinicaltrials.gov, identifier: NCT01010581).
In conclusion, so far 4SC-101 has been shown to be safe
in human clinical trials without causing arterial hypertension,
abnormal liver function tests, myelosuppression, or skin dis-
ease. Hence, 4SC-101might be as effective as leflunomide or
CYC in controlling severe SLE with fewer side effects.
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